StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note released on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

NASDAQ:TTNP opened at $5.57 on Wednesday. Titan Pharmaceuticals has a 1 year low of $5.00 and a 1 year high of $13.97. The business has a fifty day moving average of $6.67 and a 200-day moving average of $6.81.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter. Titan Pharmaceuticals had a negative return on equity of 99.96% and a negative net margin of 2,014.71%.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.